Format

Send to

Choose Destination
Retina. 2007 Oct;27(8):1026-30.

Intravitreal triamcinolone acetonide for treatment of serous macular detachment in central retinal vein occlusion.

Author information

1
Istanbul Retina Institute, Inc., Istanbul, Turkey. retina@pobox.com

Abstract

PURPOSE:

To evaluate the effect of intravitreal triamcinolone acetonide (IVTA) treatment on serous macular detachment in patients with central retinal vein occlusion (CRVO).

METHODS:

Ten eyes of 10 patients with CRVO (6 men and 4 women; age range, 54-78 years) made up the study population. The eligibility criteria for this study included clinically and angiographically detectable cystoid macular edema (CME) in which the presence of serous macular detachment was documented by optical coherence tomography (OCT). After IVTA (4 mg/0.1 mL) injection, visual and anatomical responses were observed.

RESULTS:

In all eyes, after IVTA injection, CME and serous macular detachment regressed. At 3 months and 6 months, CME and serous macular detachment had recurred in 4 (40%) and 5 eyes (50%), respectively. Patients with recurrence were retreated. No eyes lost vision at 1 month, and all eyes had improvement. At 3 months, no eyes had lost vision from baseline, and 7 eyes (70%) had improvement. At 6 months, again no eyes had lost vision from baseline, and 6 eyes (60%) maintained improved visual acuity.

CONCLUSIONS:

Our study shows that IVTA is effective treatment for serous macular detachment in patients with CRVO.

PMID:
18040239
DOI:
10.1097/IAE.0b013e3180645905
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center